Clinical Trials
10 trialsNCT03432741 2025-05-26
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Mayo Clinic
Phase 1 Terminated
NCT03719131 2025-04-22
Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy
Emory University
Phase 2 Active not recruiting
NCT01044745 2023-09-06
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer
University of Nebraska
Phase 2 Terminated
NCT01805037 2021-09-01
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas
Northwestern University
Phase 1/2 Terminated
NCT01116232 2019-03-26
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Barbara Ann Karmanos Cancer Institute
Phase 2 Terminated
NCT01419795 2017-07-27
Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
Phase 2 Terminated
NCT00072514 2017-06-29
Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00601718 2017-05-25
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
University of Washington
Phase 1/2 Completed
NCT02142335 2014-05-20
Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma
California Cancer Assocaties for Research & Excellence
Phase 2 Unknown
NCT01032122 2013-04-25
Rituximab in Metastatic Melanoma
Medical University of Vienna
Phase 1 Terminated